EarningsQ3 2026 Earnings Report
MX:SHLN Q3 2026 EPS Results
Actual EPS$14.44
Consensus EPS$10.91
Beat/MissBeat by +$3.53
One Year Ago EPS$13.20
MX:SHLN Q3 2026 Revenue Results
Actual Revenue$118.87B
Expected Revenue$116.88B
Beat/MissBeat by +$2.00B
YoY Revenue Growth+1.80%
Earnings Announcement Details
QuarterQ3 2026
Date07/31/2026
TimeBefore Open
Conference CallFriday, July 31, 2026
MX:SHLN Upcoming Earnings
Siemens Healthineers AG's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:SHLN Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call showed a mix of strong operational and product‑led momentum (notably book‑to‑bill strength, Precision Therapy/Varian growth, imaging innovations, radiopharma traction and improved cash/net‑debt) while Diagnostics weakness—driven by China's market rebasing and legacy platform dilution—kept top‑line momentum below prior expectations and led management to lower revenue guidance. Profitability and EPS were supported by tariff refunds and the synergetic core remains on track, but inflation, FX, refinancing and separation costs create tangible near‑term headwinds. Overall the positives around core growth, market share gains, strong orders and cash improvement are materially offset by the Diagnostics decline and macro/one‑off uncertainties, leaving a balanced outlook.Company Guidance
Outstanding Equipment Book‑to‑Bill
Equipment book‑to‑bill of 1.27 in Q3 (1.17 excluding new value partnerships), driven by product strength and two new U.S. value partnerships totaling several hundred million euros in equipment order intake.
Synergetic Core Growth
Imaging + Precision Therapy (the synergetic core) grew 5% in Q3; Precision Therapy grew 9% this quarter. Management expects a clear acceleration in Q4 and a decent mid‑single‑digit full‑year growth for Imaging as previously guided.
Precision Therapy & Varian Momentum
Strong ramp of new angiography (FDA approved) and Varian momentum contributing to growth; Precision Therapy margin before tariff refunds at ~14.1% in Q3 and expected continued high‑single‑digit growth from Varian over coming years.
Imaging Innovation and Market Share Gains
Photon‑counting CTs account for roughly 30% of total CT equipment order volume; U.S. CT market share has materially increased (reported to approach MRI‑level shares in the U.S.); DryCool MR technology comprises ~50% of MR units ordered, supporting differentiation and share gains.
Diagnostics Product Innovation & Radiopharma Traction
Launch of Atellica Forte (expanded assays, capillary sampling) and CE/FDA activity on brain‑health assays; radiopharmaceuticals delivered double‑digit growth and are surpassing the USD 1 billion revenue mark, including a new 8x capacity radiopharmacy in the U.K.
Profitability, Cash and Balance‑Sheet Improvements
Reported EPS guidance raised by EUR 0.15 (to EUR 2.35–2.45) due to tariff refunds; underlying EPS midpoint remains EUR 2.25 (ex‑refunds). Group profitability ex‑refunds about 15.4%; cash > EUR 1.0 billion; cash conversion 1.12; net debt reduced by ~EUR 800 million to ~EUR 12 billion; leverage improved from 3.1x to 2.8x.
Regulatory and AI Progress
Syngo.CT Coronary Cockpit received FDA approval; strong traction for AI tools in radiation therapy planning and other scalable healthcare AI deployments, supporting workflow/productivity positioning.
MX:SHLN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed